112940-39-3

Basic information

• Product Name: 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine
• Synonyms: 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine
• CAS NO: 112940-39-3
• Molecular Weight: 284.318
• Mol File: 112940-39-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine(112940-39-3)
• EPA Substance Registry System: 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine(112940-39-3)

Safety Data

• Hazardous Substances Data: 112940-39-3(Hazardous Substances Data)

Usage

Description

1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is a complex chemical compound characterized by its unique structure, which includes a piperazine ring connected to a pyridine ring and a 4-nitrophenyl group. 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine holds promise for pharmaceutical applications due to its potential interactions with biological systems, such as acting as a ligand for specific receptors in the central nervous system or serving as a substrate for enzymes. The presence of the nitro group also endows it with specific chemical reactivity, making it a candidate for further modification to develop new drug candidates or research tools. Consequently, 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is a valuable compound in the fields of medicinal chemistry and chemical biology research.

Uses

Used in Pharmaceutical Applications:
1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is used as a potential pharmaceutical agent for its ability to interact with biological systems. Its complex structure allows it to potentially act as a ligand for specific receptors in the central nervous system, making it a candidate for the development of new drugs targeting these receptors.
Used in Enzyme Substrate Research:
In the field of enzyme research, 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is used as a substrate to study the activity and specificity of certain enzymes. This can help in understanding the mechanisms of these enzymes and their roles in various biological processes.
Used in Chemical Biology Research:
1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is utilized as a research tool in chemical biology to explore its interactions with biological systems. This can lead to a better understanding of its potential applications in drug discovery and the development of novel therapeutic strategies.
Used in Medicinal Chemistry:
In medicinal chemistry, 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is used as a starting point for the design and synthesis of new drug candidates. The presence of the nitro group provides opportunities for further chemical modification, potentially leading to the creation of novel compounds with improved pharmacological properties.
Overall, 1-(4-nitro-phenyl)-4-pyridin-4-yl-piperazine is a versatile compound with a wide range of potential applications in various scientific and medical fields, making it an important compound for ongoing research and development.

Upstream product

• 34803-66-2 1-(2-pyridyl)piperazine 
• 350-46-9 4-Fluoronitrobenzene 
• 1008-91-9 4-(piperazin-1-yl)pyridine 

Downstream Products

• 1007866-95-6 C₂₅H₂₇Cl₂N₅O₃S 
• 112940-40-6 1-(4-aminophenyl)-4-(pyridin-4-yl)piperazine 

Relevant articles and documents

Design and synthesis of some new 1-phenyl-3/4-[4-(aryl/heteroaryl/alkyl-piperazine1-yl)-phenyl-ureas as potent anticonvulsant and antidepressant agents

A series of 1-phenyl-3/4-[4-(aryl/heteroaryl/alkyl-piperazine1-yl)-phenyl-urea derivatives (29–42) were designed, synthesized and evaluated for their anticonvulsant activity by using maximal electroshock (MES), subcutaneous pentylenetetrazole (scPTZ) seizure tests. The acute neurotoxicity was checked by rotarod assay. Most of the test compounds were found effective in both seizure tests. Compound 30 (1-{4-[4-(4-chloro-phenyl)-piperazin-1-yl]-phenyl}-3-phenyl-urea) exhibited marked anticonvulsant activity in MES as well as scPTZ tests. The phase II anticonvulsant quantification study of compound 30 indicates the ED50value of 28.5?mg/kg against MES induced seizures. In addition, this compound also showed considerable protection against pilocarpine induced status epilepticus in rats. Seizures induced by 3-mercaptopropionic acid model and thiosemicarbazide were significantly attenuated by compound 30, which suggested its broad spectrum of anticonvulsant activity. Interestingly, compound 30 displayed better antidepressant activity than standard drug fluoxetine. Moreover, compound 30 appeared as a non-toxic chemical entity in sub-acute toxicity studies.

NOVEL COMPOUNDS

Novel compounds which are useful for treating acute pain, visceral pain, neuropathic pain, inflammatory/pain receptor-mediated pain, tumour pain and headache diseases. The following is exemplary:

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.